2024
Investigating synergy between beta-blockers and transarterial chemoembolization in the treatment of hepatocellular carcinoma: preliminary data from a propensity matched analysis
Mutonga M, Shewarega A, Gross M, Kahl V, Madoff D. Investigating synergy between beta-blockers and transarterial chemoembolization in the treatment of hepatocellular carcinoma: preliminary data from a propensity matched analysis. Clinical Imaging 2024, 115: 110283. PMID: 39278042, DOI: 10.1016/j.clinimag.2024.110283.Peer-Reviewed Original ResearchBeta-blockersTumor responseImaging timepointsTumor sizeEtiology of liver diseaseAssociated with high mortalityTransplant free survivalTransplant-free survivalTreatment of hepatocellular carcinomaFavorable clinical outcomesChild-Pugh scoreFirst-line treatmentBeta-blocker groupPredictors of survivalCox regression analysisTreatment of HCCStudent's t-testFree survivalTransarterial chemoembolizationChi-square testPost-TACETACE treatmentPugh scoreSurvival predictorsAdjunctive use
2017
Balloon-Assisted Transarterial Chemoembolization: A Nascent Strategy for the Treatment of Hepatocellular Carcinoma
Kishore S, Cheng W, Smirniotopoulos J, Madoff D. Balloon-Assisted Transarterial Chemoembolization: A Nascent Strategy for the Treatment of Hepatocellular Carcinoma. Digestive Disease Interventions 2017, 01: 115-120. DOI: 10.1055/s-0037-1603961.Peer-Reviewed Original ResearchTransarterial chemoembolizationHepatocellular carcinomaLiver-confined hepatocellular carcinomaTreatment of HCCMajority of patientsBalloon catheter systemCancer-related mortalityLow-profile cathetersConventional transarterial chemoembolizationConventional TACECurative optionTransarterial therapiesLeading causeTherapeutic strategiesMicrocatheter technologyIntratumoral administrationChemotherapeutic agentsPatientsChemoembolizationCarcinomaTreatmentNascent strategyCatheterMajorityTherapy